Skip to main content

Table 1 Mutant P53 , P16 , and Smad4 expression in relation to clinicopathological parameters ( n = 120)

From: Clinical outcome and expression of mutant P53, P16, and Smad4 in lung adenocarcinoma: a prospective study

  Mutant P53 expression P P16 expression P Smad4 expression P
Negative (%) Positive (%) Negative (%) Positive (%) Negative (%) Positive (%)
Age ≤60 year 26 (35.6%) 47 (64.4%) 0.766 34 (46.6%) 39 (53.4%) 0.666 47 (64.4%) 26 (35.6%) 0.595
Age >60 year 18 (38.3%) 29 (61.7%)   20 (42.6%) 27 (57.4%)   28 (59.6%) 19 (40.4%)  
Male 25 (43.1%) 33 (56.9%) 0.157 27 (46.6%) 31 (53.4%) 0.741 32 (55.2%) 26 (44.8%) 0.109
Female 19 (30.6%) 43 (69.4%)   27 (43.5%) 35 (56.5%)   43 (69.4%) 19 (30.6%)  
Tumor size (cm)          
 T1 (≤3) 14 (58.3%) 10 (41.7%) 0.041 8 (33.3%) 16 (66.7%) 0.392 11 (45.8%) 13 (54.2%) 0.033
 T2 (>3 ≤ 7) 24 (32.9%) 49 (67.1%)   34 (46.6%) 39 (53.4%)   45 (61.6%) 28 (38.4%)  
 T3/4 (>7) 6 (26.1%) 17 (73.9%)   12 (52.2%) 11 (47.8%)   19 (82.6%) 4 (17.4%)  
Lymph nodes          
 Negative 27 (38.0%) 44 (62.0%) 0.709 23 (32.4%) 48 (67.6%) 0.001 38 (53.5%) 33 (46.5%) 0.014
 Positive 17 (34.7%) 32 (65.3%)   31 (63.3%) 18 (36.7%)   37 (75.5%) 12 (24.5%)  
Differentiation          
 Well 16 (50.0%) 16 (50.0%) 0.188 13 (40.6%) 19 (59.4%) 0.077 15 (46.9%) 17 (53.1%) 0.022
 Moderate 13 (31.7%) 28 (68.3%)   14 (34.1%) 27 (65.9%)   24 (58.5%) 17 (41.5%)  
 Poor 15 (31.9%) 32 (68.1%)   27 (57.4%) 20 (42.6%)   36 (76.6%) 11 (23.4%)  
Pleural invasion          
 Negative 39 (36.4%) 68 (63.6%) 0.887 47 (43.9%) 60 (56.1%) 0.497 66 (61.7%) 41 (38.3%) 0.596
 Positive 5 (38.5%) 8 (61.5%)   7 (53.8%) 6 (46.2%)   9 (69.2%) 4 (30.8%)  
Pathological stage          
 Stage I 20 (54.1%) 17 (45.9%) 0.025 11 (29.7%) 26 (70.3%) <0.001 18 (48.6%) 19 (51.4%) 0.017
 Stage II 15 (31.9%) 32 (68.1%)   17 (36.2%) 30 (63.8%)   28 (59.6%) 19 (40.4%)  
 Stage III 9 (25.0%) 27 (75.0%)   26 (72.2%) 10 (27.8%)   29 (80.6%) 7 (19.4%)  
  1. The italicized values indicate P values less than 0.05.